Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis
Abstract Background and aims The existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID‐19 crisis. However, the evide...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0111e4d5fc90471880ca6ac191ad8656 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0111e4d5fc90471880ca6ac191ad8656 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0111e4d5fc90471880ca6ac191ad86562021-12-01T04:49:15ZHyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis2045-763410.1002/cam4.4350https://doaj.org/article/0111e4d5fc90471880ca6ac191ad86562021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4350https://doaj.org/toc/2045-7634Abstract Background and aims The existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID‐19 crisis. However, the evidence for decision‐making is lacking in terms of comparison between HA and HATACE. Herein, a comprehensive evaluation was performed to compare the efficacy and safety of HATACE with monotherapy. Materials and Methods Worldwide studies were collected to evaluate the HATACE regimen for HCC due to the practical need for global extrapolation of applicative population. Meta‐analyses were performed using the RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Results Thirty‐six studies involving a large sample of 5036 patients were included finally. Compared with HA alone, HATACE produced the advantage of 5‐year overall survival (OS) rate (OR:1.90; 95%CI:1.46,2.46; p < 0.05) without increasing toxicity (p ≥ 0.05). Compared with TACE alone, HATACE was associated with superior 5‐year OS rate (OR:3.54; 95%CI:1.96,6.37; p < 0.05) and significantly reduced the incidences of severe liver damage (OR:0.32; 95%CI:0.11,0.96; p < 0.05) and ascites (OR:0.42; 95%CI:0.20,0.88; p < 0.05). Subgroup analysis results of small (≤3 cm) HCC revealed that there were no significant differences between the HATACE group and HA monotherapy group in regard to the OS rates (p ≥ 0.05). Conclusions Compared with TACE alone, HATACE was more effective and safe for HCC. Compared with HA alone, HATACE was more effective for non‐small‐sized (>3 cm) HCC with comparable safety. However, the survival benefit of adjuvant TACE in HATACE regimen was not found for the patients with small (≤3 cm) HCC.Zheng LiQiang LiXiaohu WangWeiqiang ChenXiaodong JinXinguo LiuFei YeZhongying DaiXiaogang ZhengPing LiChao SunXiongxiong LiuQiuning ZhangHongtao LuoRuifeng LiuWileyarticleCOVID‐19hepatocellular carcinomahyperthermia ablationmeta‐analysisSARS‐CoV‐2transarterial chemoembolizationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8432-8450 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
COVID‐19 hepatocellular carcinoma hyperthermia ablation meta‐analysis SARS‐CoV‐2 transarterial chemoembolization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
COVID‐19 hepatocellular carcinoma hyperthermia ablation meta‐analysis SARS‐CoV‐2 transarterial chemoembolization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zheng Li Qiang Li Xiaohu Wang Weiqiang Chen Xiaodong Jin Xinguo Liu Fei Ye Zhongying Dai Xiaogang Zheng Ping Li Chao Sun Xiongxiong Liu Qiuning Zhang Hongtao Luo Ruifeng Liu Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis |
| description |
Abstract Background and aims The existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID‐19 crisis. However, the evidence for decision‐making is lacking in terms of comparison between HA and HATACE. Herein, a comprehensive evaluation was performed to compare the efficacy and safety of HATACE with monotherapy. Materials and Methods Worldwide studies were collected to evaluate the HATACE regimen for HCC due to the practical need for global extrapolation of applicative population. Meta‐analyses were performed using the RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Results Thirty‐six studies involving a large sample of 5036 patients were included finally. Compared with HA alone, HATACE produced the advantage of 5‐year overall survival (OS) rate (OR:1.90; 95%CI:1.46,2.46; p < 0.05) without increasing toxicity (p ≥ 0.05). Compared with TACE alone, HATACE was associated with superior 5‐year OS rate (OR:3.54; 95%CI:1.96,6.37; p < 0.05) and significantly reduced the incidences of severe liver damage (OR:0.32; 95%CI:0.11,0.96; p < 0.05) and ascites (OR:0.42; 95%CI:0.20,0.88; p < 0.05). Subgroup analysis results of small (≤3 cm) HCC revealed that there were no significant differences between the HATACE group and HA monotherapy group in regard to the OS rates (p ≥ 0.05). Conclusions Compared with TACE alone, HATACE was more effective and safe for HCC. Compared with HA alone, HATACE was more effective for non‐small‐sized (>3 cm) HCC with comparable safety. However, the survival benefit of adjuvant TACE in HATACE regimen was not found for the patients with small (≤3 cm) HCC. |
| format |
article |
| author |
Zheng Li Qiang Li Xiaohu Wang Weiqiang Chen Xiaodong Jin Xinguo Liu Fei Ye Zhongying Dai Xiaogang Zheng Ping Li Chao Sun Xiongxiong Liu Qiuning Zhang Hongtao Luo Ruifeng Liu |
| author_facet |
Zheng Li Qiang Li Xiaohu Wang Weiqiang Chen Xiaodong Jin Xinguo Liu Fei Ye Zhongying Dai Xiaogang Zheng Ping Li Chao Sun Xiongxiong Liu Qiuning Zhang Hongtao Luo Ruifeng Liu |
| author_sort |
Zheng Li |
| title |
Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis |
| title_short |
Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis |
| title_full |
Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis |
| title_fullStr |
Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis |
| title_full_unstemmed |
Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis |
| title_sort |
hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: a systematic review and meta‐analysis |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://doaj.org/article/0111e4d5fc90471880ca6ac191ad8656 |
| work_keys_str_mv |
AT zhengli hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT qiangli hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiaohuwang hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT weiqiangchen hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiaodongjin hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xinguoliu hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT feiye hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT zhongyingdai hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiaogangzheng hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT pingli hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT chaosun hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiongxiongliu hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT qiuningzhang hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT hongtaoluo hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis AT ruifengliu hyperthermiaablationcombinedwithtransarterialchemoembolizationversusmonotherapyforhepatocellularcarcinomaasystematicreviewandmetaanalysis |
| _version_ |
1718405703670956032 |